STOCK TITAN

Mersana Therapeutics, Inc. - MRSN STOCK NEWS

Welcome to our dedicated page for Mersana Therapeutics news (Ticker: MRSN), a resource for investors and traders seeking the latest updates and insights on Mersana Therapeutics stock.

Mersana Therapeutics, Inc. (NASDAQ: MRSN) is a clinical-stage biopharmaceutical company dedicated to developing innovative antibody-drug conjugates (ADCs) aimed at improving the lives of cancer patients. Leveraging their proprietary Fleximer platform, Mersana is rewriting the rules for immunoconjugate therapies by creating precisely targeted and highly tailored drugs. This platform allows for the custom design of ADCs with specific properties that overcome current limitations and enhance the drug's effectiveness against particular cancers, while minimizing side effects.

Mersana's lead product candidate, Upifitamab Rilsodotin (UpRi), utilizes the Dolaflexin platform and targets the NaPi2b protein, primarily for the treatment of platinum-resistant ovarian cancer. Although the UPLIFT clinical trial did not meet its primary endpoint, the company is conducting in-depth analyses to understand the results and potential future steps for UpRi.

Among its pipeline, Mersana's early-stage programs include XMT-1660, a Dolasynthen ADC targeting B7-H4, and XMT-2056, a STING agonist ADC developed using the Immunosynthen platform, which targets a novel epitope of human epidermal growth factor receptor 2 (HER2). Mersana is advancing XMT-1660 in its Phase 1 clinical trial, with plans to initiate dose expansion in 2024. For XMT-2056, Mersana has resumed enrollment in its Phase 1 clinical trial following the lifting of a clinical hold by the FDA.

Mersana collaborates with multiple partners, such as Janssen Biotech and Merck KGaA, to advance their ADC pipelines using Mersana’s innovative platforms. Additionally, the company continues to strengthen its financial position, reporting substantial cash reserves to support its operations into 2026.

With a focus on developing next-generation ADCs, Mersana remains committed to delivering meaningful clinical benefits to cancer patients through its robust pipeline and strategic partnerships.

Rhea-AI Summary
Mersana Therapeutics, Inc. (MRSN) will be presenting at upcoming investor conferences to discuss their pipeline of antibody-drug conjugates targeting cancers. Live webcasts and archived replays will be available on their website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.17%
Tags
conferences
-
Rhea-AI Summary
Mersana Therapeutics, a clinical-stage biopharmaceutical company, will report its Q4 and full-year financial results on February 28, 2024. The company focuses on developing antibody-drug conjugates for cancer treatment.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.65%
Tags
conferences
-
Rhea-AI Summary
Mersana Therapeutics, Inc. will participate in a fireside chat at Guggenheim’s 6th Annual Biotechnology Conference on February 8, 2024. The company is a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates targeting cancers in areas of high unmet medical need.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.96%
Tags
conferences
Rhea-AI Summary
Mersana Therapeutics, Inc. (NASDAQ: MRSN) announced business updates, expected 2024 milestones, and an upcoming presentation at the 42nd Annual J.P. Morgan Healthcare Conference. The company continues to advance its Phase 1 clinical trials of XMT-1660 and XMT-2056, with plans to initiate expansion and advance dose escalation in 2024. Mersana also expects that its available funds will support its current operating plan commitments into 2026.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.73%
Tags
conferences
-
Rhea-AI Summary
Mersana Therapeutics, Inc. (NASDAQ:MRSN) granted an inducement award of 12,205 shares of its common stock to a new employee. The award was granted in accordance with Nasdaq Listing Rule 5635(c)(4) and will vest in equal annual installments over four years.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.37%
Tags
none
-
Rhea-AI Summary
Mersana Therapeutics, Inc. provided a business update and reported financial results for the third quarter ended September 30, 2023. The company is advancing dose escalation of XMT-1660 and preparing to resume enrollment for XMT-2056 in Phase 1 clinical trials. Capital resources are expected to support operating plan commitments into 2026. The company also reported net cash used in operating activities, and collaboration revenue for the quarter. Mersana will host a conference call today at 8:00 a.m. ET.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.6%
Tags
Rhea-AI Summary
Mersana Therapeutics, Inc. will provide business updates and report its financial results for Q3 2023 on November 7, 2023. The company will host a conference call and webcast at 8:00 a.m. Eastern Time. A live webcast will be available on the Mersana website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.26%
Tags
conferences earnings
-
Rhea-AI Summary
Mersana Therapeutics announces that the FDA has lifted the clinical hold on the Phase 1 clinical trial of XMT-2056, a systemically administered Immunosynthen STING-agonist ADC targeting HER2. The starting dose has been lowered based on clinical data, and the trial will evaluate safety, tolerability, exposure, and anti-tumor activity.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.21%
Tags
-
Rhea-AI Summary
Mersana Therapeutics announces retirement of Anna Protopapas as President and CEO, with Martin Huber named as her successor. Brian DeSchuytner appointed as Chief Operating Officer and Mohan Bala as Chief Development Officer. Additional changes to the executive team also announced.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.89%
Tags
none
Rhea-AI Summary
Mersana Therapeutics, Inc. (NASDAQ: MRSN) provided a business update, reporting financial results for Q2 2023. The company is focused on developing next-generation ADC platforms for cancer treatment, with a strong balance sheet supporting its operating plan commitments into 2026.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.5%
Tags

FAQ

What is the current stock price of Mersana Therapeutics (MRSN)?

The current stock price of Mersana Therapeutics (MRSN) is $1.6 as of December 20, 2024.

What is the market cap of Mersana Therapeutics (MRSN)?

The market cap of Mersana Therapeutics (MRSN) is approximately 195.2M.

What is Mersana Therapeutics, Inc.?

Mersana Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative antibody-drug conjugates (ADCs) for cancer treatment.

What platforms does Mersana use for its ADC development?

Mersana utilizes the Fleximer platform, Dolaflexin platform, Dolasynthen platform, and Immunosynthen platform for developing its ADCs.

What is Upifitamab Rilsodotin (UpRi)?

Upifitamab Rilsodotin (UpRi) is Mersana's lead product candidate, targeting the NaPi2b protein for treating platinum-resistant ovarian cancer.

What are XMT-1660 and XMT-2056?

XMT-1660 is a Dolasynthen ADC targeting B7-H4, and XMT-2056 is an Immunosynthen ADC targeting a novel HER2 epitope. Both are in Phase 1 clinical trials.

What recent clinical trial updates did Mersana report?

Mersana reported that the UPLIFT trial for UpRi did not meet its primary endpoint and announced plans for further analysis. Enrollment in the Phase 1 trial of XMT-2056 has resumed after the FDA lifted a clinical hold.

Who are Mersana's strategic partners?

Mersana partners with Janssen Biotech, Merck KGaA, and other companies to advance their ADC pipelines using Mersana’s platforms.

What is the Fleximer platform?

The Fleximer platform is Mersana’s proprietary technology that custom designs ADCs with specific properties to improve their effectiveness against cancer cells and reduce side effects.

What is Mersana's financial outlook?

Mersana has reported substantial cash reserves to support its current operating plan commitments into 2026, ensuring financial stability for its ongoing projects.

What are Mersana's future plans for XMT-1660?

Mersana plans to complete the dose escalation portion of the Phase 1 clinical trial of XMT-1660 in 2023 and initiate the dose expansion portion in 2024.

Where can investors find more information about Mersana?

Investors can find more information on the 'Investors & Media' section of Mersana’s website at www.mersana.com.

Mersana Therapeutics, Inc.

Nasdaq:MRSN

MRSN Rankings

MRSN Stock Data

195.18M
121.78M
1.26%
95.36%
7.62%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
CAMBRIDGE